Agreement - August 30, 2017
Genmab and Seattle Genetics in co-development agreement
Genmab and Seattle Genetics announces that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development. Tisotumab vedotin, […]
Agreement - August 21, 2017
Moberg Pharma divests Fiber Choice
Moberg Pharma has entered into an agreement with Caret Pharma LLC. to divest the brand Fiber Choice for a total consideration of $6.7 million plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $1.6 million. Divesting the brand enables Moberg Pharma to further focus resources on […]
Agreement - August 10, 2017
Klaria signs agreement with Purdue Pharma
Swedish Klaria and Canadian Purdue Pharma have entered into exclusive development and license and supply agreements for KL-00514 (Naloxone Buccal Film). KL-00514 is a developmental stage formulation of naloxone intended for acute treatment of intentional or accidental opioid overdose designed to give a rapid and reliable response in patients while providing a compact dosage form […]
Agreement - August 4, 2017
BioInvent and ThromboGenics amend agreement
BioInvent International and ThromboGenics NV announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The revisions to the existing agreement have been aligned with each company’s strategic ambitions and therapeutic focus. The novel anti-PIGF monoclonal antibody is currently being developed […]
Agreement - June 16, 2017
Cantargia enters collaboration agreement
Swedish Cantargia and Panorama Research Inc, a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia’s second program directed towards autoimmune and inflammatory diseases. Cantargia’s antibodies, against the molecular target IL1RAP, will be affinity matured and humanized using Panorama’s technology. In addition, Panorama will generate cell lines optimized for […]
Agreement - June 12, 2017
Dignitana partners with Piedmont Cancer Institute
Swedish Dignitana has announced that their medical device, the DigniCap scalp cooling system, will be offered at Piedmont Cancer Institute in Georgia. FDA-cleared in 2015, the DigniCap Scalp Cooling System will be available this summer at Piedmont’s center in Atlanta, with installation at other Piedmont locations to follow. The device features a patented tight-fitting silicone […]
